Bactiguard enters agreement with another leading Swedish pharmacy chain

Report this content

Bactiguard expands its presence in the market for self-care products through a new agreement with another leading Swedish pharmacy chain. The agreement covers both Bactiguard's non-alcoholic disinfection Hydrocyn and a new wound care range.

"The agreement with Apotek Hjärtat means that our products will be even more accessible, with more channels to choose from. The effective and non-alcoholic Hydrocyn disinfection is already available at, and The fact that Apotek Hjärtat includes both the disinfection and our new wound care portfolio in its range is an important milestone and quality stamp," says Andreas Wallgren, General Manager Nordics.

The proportion of self-care sold online is expected to continue to increase, as consumer behaviour is rapidly changing, driven by the pandemic. Apoteket and Apotek Hjärtat are market leaders online and together with Apotea and Meds, they account for about 65% of the self-care market1.

Bactiguard’s new wound care range

Bactiguard’s wound care range is a non-alcoholic, pH-neutral and water-based product line that can be used by both children and adults. The products are biocompatible, which means that they are not irritating to the skin or other tissue. They contain hypochlorous acid, the same substance as the body's immune cells use in their defence against infectious organisms. It means they neither smell strongly or sting, but effectively kill most viruses, bacteria and fungi that cause infections, including the new coronavirus SARS-CoV-2.2

Read more about Bactiguard’s non-alcoholic disinfection >>>
Read more about Bactiguard’s wound care range >>>

For further information, please contact:
Petra Kaur, Chief Marketing and Communication Officer, mobile +46 79 304 96 36


2. In collaboration with the Swedish Veterinary Institute (SVA), tests have been carried out with Hydrocyn aqua on a virus culture of the new Coronavirus (SARS-CoV-2) that causes covid-19. The results showed that 99.98% of the virus particles were inactivated - and thus not contagious.


About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with Bactiguard's coating are market leaders in the USA and Japan through our licensing partner BD.

Bactiguard's product portfolio also includes a non-alcoholic product line for wound care and disinfection. It effectively kills viruses, bacteria and fungi while being biocompatible, pH neutral and tissue friendly. The active ingredient hypochlorous acid is the same substance as the body's immune cells use in their defence against infectious organisms.

Bactiguard is in a strong expansion phase in the markets in Europe, China, India and the Middle East through our own product portfolio and by establishing licensing deals in new therapy areas.

Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about Bactiguard